Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 800 results for "amgen rank"

Amgen Leukemia Therapy Costs $178,000, Among Priciest Drugs

Amgen Inc. The price includes two $89,000 cycles of therapy, the median duration of treatment for patients who responded in clinical studies, said Danielle Bertrand, an Amgen spokeswoman. The drug was approved by U.S. regulators on Dec. 3 for ... BusinessWeek, 15 hours ago

2 images for "amgen rank"

Velo News, 5 days ago
AdvisorOne, 1 month ago

Amgen Leukemia Treatment to Cost $178,000, Among Priciest Drugs

Amgen Inc. (AMGN) 's leukemia drug Blincyto will cost $178,000 for a standard course of treatment, continuing a trend of high prices for immunotherapy, the newest wave of cancer treatments. The price includes two $89,000 cycles of therapy, the ...
 Bloomberg18 hours ago

FDA Approves Amgen's XGEVA® Denosumab For The Treatment Of Hypercalcemia Of Malignancy Refractory To Bisphosphonate Therapy

By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- Amgen (NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for XGEVA(®) (denosumab) for the treatment of hypercalcemia of ...
 4 Traders11 hours ago Amgen's Xgeva gets US FDA approval to treat hypercalcemia of malignancy refractory to bisphosphonate therapy  PharmaBiz1 week ago Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of malignancy  News-Medical.Net1 week ago FDA Approves Amgen (AMGN)'s XGEVA (Denosumab) For The Treatment Of Hypercalcemia Of Malignancy Refractory To Bisphosphonate Therapy 12/8/2014  ClinicSpace1 week ago
[x]  

The Zacks Analyst Blog Highlights: Novartis, Amgen, Incyte and Allergan

For Immediate Release Chicago, IL December 10, 2014 Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.
 Yahoo! Finance1 week ago The Zacks Analyst Blog Highlights:Cubist Pharmaceuticals, bluebird bio, Amgen, Incyte and Array  Individual.com6 days ago THE ZACKS ANALYST BLOG HIGHLIGHTS : Biogen Idec, Eli Lilly, AstraZeneca and Amgen  4 Traders1 week ago The Zacks Analyst Blog Highlights:BioMarin, Prosensa, Five Prime Therapeutics, AbbVie, Amgen, Biogen and Vertex  Reliance Trust2 weeks ago
[x]  

Amgen (AMGN) Trading Near $166.92 Resistance Level

After closing Monday at $159.60, Amgen Inc ( AMGN ) presents an attractive opportunity to get a 8.30% return in just 122 days, which is an annualized return of 24.84% (for comparison purposes only). To enter this trade, sell one Apr. '15 $165.00 ...
 TradingCharts.com1 day ago Amgen (AMGN) Trading Near $171.46 Resistance Level  Individual.com6 days ago Amgen (AMGN) Trading Near $171.00 Resistance Level  TradingCharts.com2 weeks ago Amgen (AMGN) Trading Near $166.38 Resistance Level  TradingCharts.com2 weeks ago

Amgen Successfully Expands Xgeva Label in the U.S.

Amgen 's ( AMGN ) Xgeva was approved by the FDA for another indication in the U.S. Xgeva's label was expanded for the treatment of hypercalcemia of malignancy (:HCM) refractory to bisphosphonate therapy. Amgen's shares gained 1.4% following the ...
 Yahoo! Finance1 week ago

Amgen Unveils Positive Results from Blood Cancer Studies

Amgen ( AMGN ) announced positive results from two blood cancer studies on Kyprolis and Blincyto. The company announced encouraging detailed results from its phase III ASPIRE (cArfilzomib, lenalidomide, and dexamethaSone versus lenalidomide and ...
 Yahoo! Finance1 week ago
[x]  

Amgen's Blincyto Gets FDA Nod, Carries Boxed Warning

Amgen Inc. 's ( AMGN ) Blincyto (blinatumomab) gained FDA approval for the treatment of patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia ( ALL ). This makes Blincyto the first ...
 Yahoo! Finance1 week ago
[x]  

AstraZeneca/Amgen's Brodalumab Excels in Psoriasis Study

AstraZeneca ( AZN ) and partner Amgen ( AMGN ) announced encouraging results from the pivotal, multi-arm phase III AMAGINE-2 study (n>1800) on their psoriasis candidate, brodalumab. The study compared brodalumab with both Johnson & Johnson's ( JNJ ) ...
 Yahoo! Finance3 weeks ago
[x]  

Potential Amgen (AMGN) Trade Has 1.52% Downside Protection

After FridayaEUR(TM)s trading in Amgen Inc (http://www.marketintelligencecenter.com/symbol/AMGN"AMGN) MarketIntelligenceCenter.com's patented algorithms uncovered a trade that offers a 6.03% return or 40.77% on an annualized basis (for comparison ...
 Individual.com3 weeks ago Potential Amgen (AMGN) Trade Targets 6.14% Return  TradingCharts.com3 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less